Wang Xiaohui, Li Xiaolei, Fu Xiaoyu, Bai Miaomiao, Li Xiang, Mei Qian, Nie Jing, Wu Zhiqiang, Han Weidong
Department of Molecular Biology, Institute of Basic Medicine, School of Life Sciences, Chinese PLA General Hospital, Beijing 100853, China.
Curr Protein Pept Sci. 2015;16(4):270-8. doi: 10.2174/138920371604150429151457.
Tumor recurrence followed by chemoresistance is a major cause of the poor survival rates for ovarian cancer. Despite advances in ovarian cancer chemotherapies and increased knowledge of the characteristics of ovarian cancer, chemoresistance is still an enormous clinical challenge. Current research suggests that ovarian cancer stem cells (OCSCs) might be involved in the occurrence of chemoresistance in ovarian cancer. In this review, we focus on the relationship of ovarian cancer stem cells with drug-resistant ovarian cancer phenotypes. We also discuss the current knowledge regarding ovarian cancer stem cell-based therapeutic strategies as attempts to overcome chemoresistance, the largest obstacle for successful treatment. Finally, we discuss methods for improving the treatment outcomes of ovarian cancer patients with chemoresistance.
肿瘤复发并伴有化疗耐药是卵巢癌生存率低的主要原因。尽管卵巢癌化疗取得了进展，且对卵巢癌特征的了解有所增加，但化疗耐药仍然是一个巨大的临床挑战。目前的研究表明，卵巢癌干细胞（OCSCs）可能参与了卵巢癌化疗耐药的发生。在本综述中，我们重点关注卵巢癌干细胞与耐药性卵巢癌表型之间的关系。我们还讨论了目前有关基于卵巢癌干细胞的治疗策略的知识，这些策略旨在克服化疗耐药这一成功治疗的最大障碍。最后，我们讨论了改善化疗耐药卵巢癌患者治疗效果的方法。
